Stratview Research publishes a new report titled Chronic Idiopathic Constipation (CIC) Drugs Market which is segmented By Product Type (Lubiprostone, Linaclotide, Others), End-User (Hospitals & Clinics, Ambulatory Surgical Centres, Long Term Care Centres, Others), and Region.
The Chronic Idiopathic Constipation (CIC) Drugs market is projected to grow from USD 4.38 billion in 2021 to USD 6.93 billion by 2028 at a CAGR of around 6.72% during the forecast period of 2022-2028. The growth of the chronic idiopathic constipation (CIC) drugs market is primarily driven by increasing incidences of chronic constipation health disorder. Expanding geriatric populace across geographies coupled with rising spending on healthcare is expected to propel the market growth at a significant rate during the review period. Additionally, a growing emphasis on research and development activities for novel drug development is likely to create lucrative opportunities for the market players during the review period.
Why is this report beneficial?
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
It also offers –
- Market Overview
- Key Manufacturers Profiles
- Market Analysis by Region
- Market Segment by Type
- Market Segment by Application
- Raw Material and Supply Chain
- Other Key Research Findings
All the data compiled by the market experts is the outcome of rigorous primary and secondary research conducted on the market players and reliable sources, including company white papers, journals, press releases, and more.
Key players active in the market –
The following are some of the key players in the Chronic Idiopathic Constipation (CIC) Drugs Market:
- Actavis Generics (US)
- The Chugai Pharmaceutical Co., Ltd (Japan)
- Ferring International Center, S.A. (Switzerland)
- Synergy Pharmaceuticals (US)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Hoffmann-La Roche AG (Switzerland)
- Sanofi S.A. (France)
- Bayer AG (Germany)
- Salix Pharmaceuticals, Inc. (US)
- Sucampo Pharmaceuticals, Inc. (US)
- Ironwood Pharmaceuticals, Inc (US)
- Progenics Pharmaceuticals, Inc. (US).
Click here to get a free sample copy of this report: https://www.stratviewresearch.com/Request-Sample/2406/Chronic-Idiopathic-Constipation-(CIC)-Drugs-Market.html#form
Customization of the report –
At Stratview Research, the market researchers make a note of opportunities, drawbacks/bottlenecks, estimations, and information related to the market using experienced skills and verified methodologies. Our research reports offer an exceptional experience of innovative solutions and outcomes to the users. If required, user can also opt for customization of the report.
Connect with our team at –
E-mail: [email protected]